Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Tran, Pierre V.
Tollefson, Gary D.
Sanger, Todd M.
Lu, Yili
Berg, Paul H.
and
Beasley, Charles M.
1999.
Olanzapine versus haloperidol in the treatment of schizoaffective disorder.
British Journal of Psychiatry,
Vol. 174,
Issue. 1,
p.
15.
Massie, Jennifer
and
Lewis, Shôn
1999.
Duration of treatment in schizophrenia.
The Journal of Forensic Psychiatry,
Vol. 10,
Issue. 3,
p.
491.
Green, Ben
1999.
Focus on Olanzapine.
Current Medical Research and Opinion,
Vol. 15,
Issue. 2,
p.
79.
Fleischhacker, W. Wolfgang
1999.
Invited comment.
Acta Psychiatrica Scandinavica,
Vol. 100,
Issue. 4,
p.
314.
Stephenson, C. M. E.
and
Pilowsky, L. S.
1999.
Psychopharmacology of olanzapine.
British Journal of Psychiatry,
Vol. 174,
Issue. S38,
p.
52.
Fleischhacker, W. Wolfgang
1999.
The psychopharmacology of schizophrenia.
Current Opinion in Psychiatry,
Vol. 12,
Issue. 1,
p.
53.
Kane, John
1999.
Olanzapine in the long-term treatment of schizophrenia.
British Journal of Psychiatry,
Vol. 174,
Issue. S37,
p.
26.
Tollefson, Gary D.
and
Taylor, Cindy C.
2000.
Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent.
CNS Drug Reviews,
Vol. 6,
Issue. 4,
p.
303.
Revicki, Dennis A
2000.
The new atypical antipsychotics: a review of pharmacoeconomic studies.
Expert Opinion on Pharmacotherapy,
Vol. 1,
Issue. 2,
p.
249.
Lund, Brian C
and
Perry, Paul J
2000.
Olanzapine: an atypical antipsychotic for schizophrenia.
Expert Opinion on Pharmacotherapy,
Vol. 1,
Issue. 2,
p.
305.
Dose, M.
2000.
Langzeittherapie der Schizophrenie.
p.
37.
Sacristán, José A.
Gómez, Juan-Carlos
Montejo, Angel-Luis
Vieta, Eduardo
and
Gregor, Karl J.
2000.
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study.
Clinical Therapeutics,
Vol. 22,
Issue. 5,
p.
583.
Fleischhacker, W. W.
2000.
Psychiatrie der Gegenwart 5.
p.
209.
Möller, Hans-Jürgen
2000.
Definition, Psychopharmacological Basis and Clinical Evaluation of Novel/Atypical Neuroleptics: Methodological Issues and Clinical Consequences.
The World Journal of Biological Psychiatry,
Vol. 1,
Issue. 2,
p.
75.
Meltzer, Herbert Y.
2000.
Atypical Antipsychotics.
p.
191.
Marder, Stephen R.
2000.
Newer antipsychotics.
Current Opinion in Psychiatry,
Vol. 13,
Issue. 1,
p.
11.
Duggan, L
Fenton, M
Dardennes, RM
El-Dosoky, A
and
Indran, S
2000.
Cochrane Database of Systematic Reviews.
Ishigooka, Jun
Inada, Toshiya
and
Miura, Sadanori
2001.
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the Japan multicenter, double‐blind olanzapine trial.
Psychiatry and Clinical Neurosciences,
Vol. 55,
Issue. 4,
p.
403.
Weigmann, Harald
Gerek, Sevda
Zeisig, Alexander
Müller, Matthias
Härtter, Sebastian
and
Hiemke, Christoph
2001.
Fluvoxamine But Not Sertraline Inhibits the Metabolism of Olanzapine: Evidence From A Therapeutic Drug Monitoring Service.
Therapeutic Drug Monitoring,
Vol. 23,
Issue. 4,
p.
410.
Kane, John
2001.
Progress defined-short-term efficacy, long-term effectiveness.
International Clinical Psychopharmacology,
Vol. 16,
Issue. Supplement 1,
p.
S1.
eLetters
No eLetters have been published for this article.